DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...
If you are trying to work out whether CRISPR Therapeutics is attractively priced or not, starting with the recent share ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it
CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.
Researchers identified AlCas12a, a compact, versatile enzyme that improves CRISPR gene editing and enables faster molecular ...
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...
What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology ...
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
When Feng Zhang was in his early 30s, he used a set of genes found in bacteria called CRISPR to pioneer a new kind of gene ...
Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results